Lyfgenia

Gene therapy uptake in sickle cell stays slow, despite patient interest
BioPharma Dive
Mon, 12/9/24 - 10:37 am
gene therapy
sickle cell disease
patients
Casgevy
Lyfgenia
Bluebird Bio
Vertex Pharmaceuticals
Why some gene therapies face sluggish launches
Medical Marketing and Media
Mon, 09/16/24 - 10:21 pm
gene therapy
Bluebird Bio
Lyfgenia
drug launches
Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia
Fierce Pharma
Wed, 08/14/24 - 10:31 pm
Bluebird Bio
sickle cell disease
Vertex Pharmaceuticals
Lyfgenia
Casgevy
First Patient Begins Newly Approved Sickle Cell Gene Therapy
NY Times, NY
Mon, 05/6/24 - 11:40 am
Bluebird Bio
gene therapy
sickle cell disease
patients
Lyfgenia
Bluebird Extends Cash Runway with $175M Financing to Support Gene Therapy Launch
BioSpace
Tue, 03/19/24 - 11:22 am
Bluebird Bio
funding
sickle cell disease
Lyfgenia
Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan
Fierce Pharma
Mon, 03/11/24 - 11:33 am
Bluebird Bio
Michigan
lovo-cel
Lyfgenia
Medicaid
sickle cell disease
gene therapy
Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal
Fierce Pharma
Thu, 01/4/24 - 11:37 am
Bluebird Bio
Lyfgenia
sickle cell disease
gene therapy
Bluebird’s Newly Approved SCD Gene Therapy Faces Rough Road with Hefty Price Tag, Boxed Warning
BioSpace
Mon, 12/11/23 - 11:20 am
Bluebird Bio
sickle cell disease
Lyfgenia
gene therapy
CRISPR
FDA approves bluebird's sickle cell disease gene therapy. Can Lyfgenia overcome CRISPR's halo?
Fierce Pharma
Sun, 12/10/23 - 11:15 pm
Bluebird Bio
sickle cell disease
FDA
CRISPR
Lyfgenia